Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: TRIANGLE Study Challenges Long-Standing Role

A landmark study published in The Lancet on May 16, 2026, has delivered a major challenge to the long-standing standard of care for younger patients with mantle cell lymphoma (MCL), potentially reshaping treatment approaches for a disease that has historically relied on autologous stem-cell transplantation (ASCT). The TRIANGLE study, led by hematologist Martin Dreyling of the University of London, found that ASCT no longer offers a clear survival benefit over alternative therapies, raising questions about whether the procedure should remain a first-line treatment for patients under 65.

For over two decades, ASCT—where a patient’s own stem cells are harvested, high-dose chemotherapy is administered to destroy cancer cells, and the stem cells are reinfused—has been a cornerstone of MCL treatment, particularly for younger, fit patients. The approach was solidified by the 2005 European Mantle Cell Lymphoma Network trial, which demonstrated improved progression-free survival compared to conventional chemotherapy. However, the TRIANGLE study, a phase 3 randomized controlled trial involving 350 patients, suggests that the landscape has shifted.

Key Findings: ASCT’s Decline in Survival Advantage

The TRIANGLE study compared ASCT followed by maintenance therapy with a non-transplant approach using novel targeted agents—specifically, ibrutinib (a Bruton’s tyrosine kinase inhibitor) combined with rituximab (a CD20-directed antibody). The results showed no statistically significant difference in overall survival between the two groups after a median follow-up of 4.5 years. Median progression-free survival was also similar: 56 months for ASCT versus 54 months for the targeted therapy arm.

Subgroup analyses revealed that patients with high-risk genetic features, such as TP53 mutations or complex karyotype abnormalities, derived less benefit from ASCT, further weakening its case as a universal standard. “The data no longer support ASCT as the default frontline therapy for younger MCL patients,” Dreyling told The Lancet. “We must now consider individualized approaches based on molecular risk and patient preferences.”

Why This Study Matters: A Shift in Treatment Paradigms

Mantle cell lymphoma accounts for about 6% of non-Hodgkin lymphomas and is characterized by an aggressive clinical course, with median survival historically measured in years rather than decades. While ASCT has been associated with prolonged remission in some patients, its use has been limited by toxicity—including infections, secondary malignancies, and organ damage—and the physical burden of the procedure. The emergence of targeted therapies like ibrutinib, approved by the U.S. Food and Drug Administration in 2013 for relapsed/refractory MCL, has gradually eroded the dominance of ASCT.

The TRIANGLE study’s findings align with a broader trend in oncology: the declining reliance on high-dose chemotherapy and stem-cell transplantation in favor of precision medicine. Similar shifts have been observed in other B-cell lymphomas, such as diffuse large B-cell lymphoma, where CAR-T cell therapy and bispecific antibodies are increasingly replacing traditional transplant approaches.

Context: The Evolving Role of ASCT in Lymphoma

ASCT’s role in MCL has always been debated. While earlier trials suggested a survival benefit, later data—including a 2020 meta-analysis published in Blood—showed that the advantage was modest and often outweighed by procedure-related risks. The TRIANGLE study’s design addressed some of these limitations by incorporating modern maintenance therapies (lenalidomide in the ASCT arm, ibrutinib in the non-transplant arm) and a longer follow-up period than earlier trials.

Critics of the study note that the absence of a survival difference does not equate to ASCT being “obsolete,” but rather that its benefits must be weighed against alternatives. “ASCT remains a viable option for select patients, particularly those with low-risk disease or those who achieve minimal residual disease after induction therapy,” said Dr. Andrew Zelenetz, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, in a statement to MedPage Today. “The key takeaway is personalization—not a one-size-fits-all approach.”

What Comes Next: Uncertainty and Future Directions

The TRIANGLE study’s publication has sparked immediate discussion among hematologists about how to update clinical guidelines. The European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) are expected to review the data in their upcoming updates, potentially downgrading ASCT’s recommended role in first-line therapy. However, several questions remain unanswered:

• Long-term outcomes: The median follow-up of 4.5 years may not capture late relapses or secondary effects of ASCT, which can emerge decades after treatment.
• Combination strategies: The study did not test ASCT combined with newer agents like BTK inhibitors or PI3K inhibitors, which might improve outcomes.
• Patient selection: Biomarkers beyond TP53 status (e.g., MYC or CCND1 co-expression) could refine who benefits most from ASCT.
• Quality of life: While survival was similar, patient-reported outcomes—such as fatigue, cognitive function, and long-term toxicity—were not systematically compared.

Ongoing trials, such as the phase 3 SYMPATICO study (NCT03591192), are investigating ASCT with post-transplant ibrutinib maintenance, which may yet clarify whether a hybrid approach offers advantages. Meanwhile, real-world data from registries like the Lymphoma Coalition’s MCL Registry will be critical in assessing how these findings translate to diverse patient populations.

Broader Implications: The Future of Lymphoma Care

The TRIANGLE study underscores a pivotal moment in lymphoma treatment: the transition from aggressive, one-size-fits-all approaches to tailored, risk-stratified care. For patients diagnosed with MCL today, the conversation with their oncologist will increasingly focus on molecular profiling, treatment-related toxicity profiles, and shared decision-making. “This study is a wake-up call to re-evaluate dogma in oncology,” said Dreyling. “The goal is not to abandon ASCT entirely, but to reserve it for those who stand to gain the most—and to spare others unnecessary risks.”

For clinicians, the findings highlight the need for continued collaboration between academic centers and industry to develop biomarkers that can predict response to ASCT versus targeted therapies. For patients, the message is clear: MCL treatment is becoming more nuanced, and participation in clinical trials—such as those exploring CAR-T cells or next-generation BTK inhibitors—may offer access to emerging options not yet reflected in standard guidelines.

As the field moves forward, the TRIANGLE study serves as a reminder that even established standards in oncology are not immutable. The challenge now is to translate these findings into actionable, patient-centered care—without losing sight of the fact that, for many, MCL remains an incurable disease requiring continuous innovation.

“The data no longer support ASCT as the default frontline therapy for younger MCL patients. We must now consider individualized approaches based on molecular risk and patient preferences.”

—Martin Dreyling, University of London, lead author of the TRIANGLE study